Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.24
- Piotroski Score 8.00
- Grade Market Outperform
- Symbol (CVAC)
- Company CureVac N.V.
- Price $2.67
- Changes Percentage (4.31%)
- Change $0.11
- Day Low $2.53
- Day High $2.67
- Year High $6.30
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/23/2025
- Fiscal Year End N/A
- Average Stock Price Target $29.00
- High Stock Price Target $37.00
- Low Stock Price Target $21.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.33
- Trailing P/E Ratio -3.38
- Forward P/E Ratio -3.38
- P/E Growth -3.38
- Net Income $-260,167,000
Income Statement
Quarterly
Annual
Latest News of CVAC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...
CureVac NV faces competition in the vaccine market and is focused on differentiating its mRNA technology. The company collaborates with GSK in oncology and infectious diseases, exploring new opportuni...
By Yahoo! Finance | 1 week ago -
We Think CureVac (NASDAQ:CVAC) Can Afford To Drive Business Growth
Although a company's lack of profitability does not guarantee a stock decline, monitoring cash burn is crucial. For instance, CureVac (NASDAQ:CVAC) had €300m in cash reserves and a €312m cash burn...
By Yahoo! Finance | 3 months ago -
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 47% Undervalued
The article discusses using the Discounted Cash Flow (DCF) model to estimate the intrinsic value of CureVac N.V. (NASDAQ:CVAC), indicating a higher analyst price target than the fair value estimate....
By Yahoo! Finance | 4 months ago
